JP Morgan Chase’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $785M | Sell |
2,675,517
-3,648,235
| -58% | -$1.1B | 0.04% | 331 |
|
|
2026
Q1 | $2B | Buy |
6,323,752
+1,603,753
| +34% | +$546M | 0.13% | 162 |
|
|
2025
Q4 | $1.88B | Buy |
4,719,999
+176,229
| +4% | +$78M | 0.12% | 178 |
|
|
2025
Q3 | $2.07B | Buy |
4,543,770
+2,481,762
| +120% | +$1.01B | 0.12% | 166 |
|
|
2025
Q2 | $672M | Sell |
2,062,008
-156,864
| -7% | -$43.4M | 0.04% | 354 |
|
|
2025
Q1 | $599M | Sell |
2,218,872
-31,188
| -1% | -$8.02M | 0.04% | 346 |
|
|
2024
Q4 | $529M | Buy |
2,250,060
+87,116
| +4% | +$22.9M | 0.04% | 371 |
|
|
2024
Q3 | $595M | Buy |
2,162,944
+390,073
| +22% | +$102M | 0.05% | 343 |
|
|
2024
Q2 | $431M | Buy |
1,772,871
+24,682
| +1% | +$3.9M | 0.04% | 411 |
|
|
2024
Q1 | $261M | Sell |
1,748,189
-1,267,952
| -42% | -$212M | 0.02% | 567 |
|
|
2023
Q4 | $577M | Sell |
3,016,141
-70,705
| -2% | -$12M | 0.06% | 320 |
|
|
2023
Q3 | $547M | Sell |
3,086,846
-46,128
| -1% | -$8.8M | 0.06% | 294 |
|
|
2023
Q2 | $595M | Buy |
3,132,974
+38,240
| +1% | +$7.58M | 0.06% | 290 |
|
|
2023
Q1 | $620M | Sell |
3,094,734
-32,960
| -1% | -$6.93M | 0.08% | 272 |
|
|
2022
Q4 | $743M | Buy |
3,127,694
+582,662
| +23% | +$124M | 0.1% | 218 |
|
|
2022
Q3 | $509M | Buy |
2,545,032
+261,395
| +11% | +$49.9M | 0.07% | 264 |
|
|
2022
Q2 | $333M | Sell |
2,283,637
-635,378
| -22% | -$90.1M | 0.05% | 368 |
|
|
2022
Q1 | $477M | Sell |
2,919,015
-53,070
| -2% | -$8.09M | 0.06% | 316 |
|
|
2021
Q4 | $504M | Buy |
2,972,085
+526,426
| +22% | +$97.8M | 0.06% | 331 |
|
|
2021
Q3 | $462M | Sell |
2,445,659
-142,851
| -6% | -$26.8M | 0.06% | 332 |
|
|
2021
Q2 | $439M | Buy |
2,588,510
+410,109
| +19% | +$60.1M | 0.05% | 366 |
|
|
2021
Q1 | $308M | Sell |
2,178,401
-126,049
| -5% | -$19M | 0.04% | 448 |
|
|
2020
Q4 | $300M | Buy |
2,304,450
+29,185
| +1% | +$3.9M | 0.04% | 409 |
|
|
2020
Q3 | $330M | Buy |
2,275,265
+52,378
| +2% | +$7.44M | 0.06% | 330 |
|
|
2020
Q2 | $329M | Buy |
2,222,887
+1,380,042
| +164% | +$186M | 0.06% | 300 |
|
|
2020
Q1 | $91.7M | Buy |
842,845
+250,331
| +42% | +$28.9M | 0.02% | 593 |
|
|
2019
Q4 | $68.2M | Sell |
592,514
-55,922
| -9% | -$5.58M | 0.01% | 812 |
|
|
2019
Q3 | $52.1M | Sell |
648,436
-16,401
| -2% | -$1.3M | 0.01% | 927 |
|
|
2019
Q2 | $47.3M | Buy |
664,837
+12,898
| +2% | +$990K | 0.01% | 997 |
|
|
2019
Q1 | $60.9M | Buy |
651,939
+206,129
| +46% | +$17.2M | 0.01% | 869 |
|
|
2018
Q4 | $32.5M | Sell |
445,810
-540,036
| -55% | -$41.5M | 0.01% | 1136 |
|
|
2018
Q3 | $86.3M | Buy |
985,846
+352,794
| +56% | +$35.5M | 0.02% | 771 |
|
|
2018
Q2 | $62.3M | Buy |
633,052
+577,251
| +1,034% | +$57.3M | 0.01% | 860 |
|
|
2018
Q1 | $6.64M | Buy |
55,801
+42,382
| +316% | +$5.46M | ﹤0.01% | 2339 |
|
|
2017
Q4 | $1.71M | Sell |
13,419
-1,614
| -11% | -$203K | ﹤0.01% | 3411 |
|
|
2017
Q3 | $1.78M | Sell |
15,033
-40,233
| -73% | -$3.43M | ﹤0.01% | 3223 |
|
|
2017
Q2 | $4.41M | Sell |
55,266
-7,720
| -12% | -$493K | ﹤0.01% | 2555 |
|
|
2017
Q1 | $3.23M | Buy |
62,986
+6,678
| +12% | +$309K | ﹤0.01% | 2727 |
|
|
2016
Q4 | $2.11M | Buy |
56,308
+29,712
| +112% | +$1.24M | ﹤0.01% | 3043 |
|
|
2016
Q3 | $1.8M | Sell |
26,596
-4,348
| -14% | -$307K | ﹤0.01% | 2853 |
|
|
2016
Q2 | $1.72M | Sell |
30,944
-7,218
| -19% | -$455K | ﹤0.01% | 2891 |
|
|
2016
Q1 | $2.4M | Buy |
38,162
+450
| +1% | +$29.9K | ﹤0.01% | 2605 |
|
|
2015
Q4 | $3.55M | Sell |
37,712
-116,201
| -75% | -$10.8M | ﹤0.01% | 2430 |
|
|
2015
Q3 | $12.4M | Sell |
153,913
-138,689
| -47% | -$15.4M | ﹤0.01% | 1598 |
|
|
2015
Q2 | $35.1M | Sell |
292,602
-233,727
| -44% | -$27.9M | 0.01% | 1057 |
|
|
2015
Q1 | $55M | Sell |
526,329
-122,099
| -19% | -$12.4M | 0.01% | 851 |
|
|
2014
Q4 | $62.9M | Buy |
648,428
+143,864
| +29% | +$13.3M | 0.01% | 832 |
|
|
2014
Q3 | $39.4M | Sell |
504,564
-5,289
| -1% | -$341K | 0.01% | 1024 |
|
|
2014
Q2 | $32.2M | Buy |
509,853
+99,216
| +24% | +$5.9M | 0.01% | 1074 |
|
|
2014
Q1 | $27.6M | Buy |
410,637
+124,155
| +43% | +$9.61M | 0.01% | 1142 |
|
|
2013
Q4 | $18.4M | Sell |
286,482
-14,210
| -5% | -$848K | 0.01% | 1378 |
|
|
2013
Q3 | $19.2M | Buy |
300,692
+31,105
| +12% | +$1.55M | 0.01% | 1349 |
|
|
2013
Q2 | $8.36M | Buy |
+269,587
| New | +$7.17M | ﹤0.01% | 1790 |
|
Other funds holding ALNY
JP Morgan Chase's ALNY Position: Q2 2026 in Review
JP Morgan Chase reduced its Alnylam Pharmaceuticals (ALNY) stake by 58% in Q2 2026, selling an estimated $1.1B and leaving 2,675,517 shares worth $785M. The position accounts for 0.04% of the portfolio, ranked #331.
JP Morgan Chase first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.07B in Q3 2025. 496 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- JP Morgan Chase held 2,675,517 shares of Alnylam Pharmaceuticals worth $785M as of Q2 2026.
- JP Morgan Chase sold 3,648,235 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.1B.
- Alnylam Pharmaceuticals made up 0.04% of JP Morgan Chase's portfolio in Q2 2026, its #331 holding.
- JP Morgan Chase first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- JP Morgan Chase's Alnylam Pharmaceuticals position peaked at $2.07B in Q3 2025.
- 496 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.